10-Q: Amphastar Q3 2025: BAQSIMI Drives Revenue Amidst Litigation

Amphastar Pharmaceuticals reports mixed Q3 2025 results with strong BAQSIMI sales growth offset by increased litigation expenses and declines in other key products.

Summary

• Net revenues for Q3 2025 were $191.84 million, a slight increase from $191.214 million in Q3 2024.
• Net revenues for the nine months ended September 30, 2025, were $536.782 million, down from $545.444 million in the same period of 2024.
• BAQSIMI sales grew 33% in Q3 2025 to $53.608 million and 63% for the nine months to $138.650 million, driven by expanded marketing and full distribution responsibility.
• Primatene MIST sales increased 11% in Q3 2025 to $28.808 million and 10% for the nine months to $80.739 million.
• Glucagon sales decreased 49% in Q3 2025 to $13.558 million and 33% for the nine months to $55.003 million due to competition and a shift to ready-to-use products.
• Epinephrine sales decreased 12% in Q3 2025 to $18.789 million and 29% for the nine months to $53.556 million due to lower average selling price and increased competition.
• Lidocaine sales decreased 19% in Q3 2025 to $12.932 million due to other suppliers returning to historical distribution levels.
• Gross profit decreased by 3% in Q3 2025 to $98.646 million (51% margin) from $101.941 million (53% margin) in Q3 2024.
• General and administrative expenses surged 166% in Q3 2025 to $39.467 million and 59% for the nine months to $69.454 million, primarily due to a $23.1 million litigation provision.
• Net income for Q3 2025 was $17.350 million ($0.37 diluted EPS), down from $40.429 million ($0.78 diluted EPS) in Q3 2024.
• Net income for the nine months was $73.665 million ($1.52 diluted EPS), down from $121.555 million ($2.32 diluted EPS) in the prior year.
• Cash and cash equivalents increased to $216.265 million as of September 30, 2025, from $151.609 million at December 31, 2024.
• The company purchased 172,920 shares for $4.9 million in Q3 2025 and 2,108,616 shares for $54.9 million for the nine months under its share buyback program.
• A jury verdict on October 22, 2025, awarded a plaintiff $34.1 million in a personal injury lawsuit, of which $11.0 million is covered by insurance, and $23.1 million was accrued in Q3 2025.
• Entered into a License Agreement with Nanjing Anji Biotechnology Co., Ltd. in August 2025 for exclusive rights to develop and commercialize three products in the US and Canada, involving upfront and potential milestone payments up to $267.0 million and royalties.
• Entered into a Distribution Agreement with Nanjing Chengong Pharmaceutical Co., Limited in October 2025 for exclusive distribution of BAQSIMI in Greater China.

Sentiment

Score: 4

Explanation: While BAQSIMI and Primatene MIST showed strong growth and a new product was launched, the substantial decline in net income and EPS, coupled with a significant litigation expense and declining sales of other key products, indicates a challenging quarter. The increased R&D investment and share buyback are positive long-term signals, but the immediate financial performance is concerning.

Positives

• BAQSIMI sales increased significantly by 33% in Q3 2025 to $53.608 million and 63% for the nine months to $138.650 million, driven by expanded marketing and full distribution responsibility.
• Primatene MIST sales grew by 11% in Q3 2025 to $28.808 million and 10% for the nine months to $80.739 million due to continued marketing efforts.
• Successful launch of Iron Sucrose Injection in August 2025, contributing $2.4 million in sales in Q3.
• Cash and cash equivalents increased to $216.265 million as of September 30, 2025, from $151.609 million at December 31, 2024, indicating a strong cash position.
• The Board authorized an additional $50.0 million increase to the share buyback program in August 2025, bringing the total authorization to $435.0 million, demonstrating commitment to shareholder returns.
• FDA approved Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials in August 2025.
• Entered into a License Agreement with Nanjing Anji Biotechnology Co., Ltd. in August 2025 for exclusive rights to develop and commercialize three new products in the US and Canada, expanding the product pipeline.
• Entered into a Distribution Agreement with Nanjing Chengong Pharmaceutical Co., Limited in October 2025 for exclusive distribution of BAQSIMI in Greater China, potentially expanding market reach for a key product.

Negatives

• Overall net revenues for the nine months ended September 30, 2025, decreased by 2% to $536.782 million compared to $545.444 million in the prior year.
• Net income significantly decreased by 57% in Q3 2025 to $17.350 million and 39% for the nine months to $73.665 million, primarily due to increased operating expenses.
• Diluted EPS decreased from $0.78 to $0.37 in Q3 2025 and from $2.32 to $1.52 for the nine months.
• Glucagon sales declined substantially by 49% in Q3 2025 to $13.558 million and 33% for the nine months to $55.003 million due to competition and market shift.
• Epinephrine sales decreased by 12% in Q3 2025 to $18.789 million and 29% for the nine months to $53.556 million due to lower pricing and increased competition.
• Lidocaine sales decreased by 19% in Q3 2025 to $12.932 million due to competitors returning to historical distribution levels.
• Gross profit margins decreased from 53% to 51% in Q3 2025 and from 53% to 50% for the nine months, impacted by lower pricing on higher-margin products and increased labor costs.
• General and administrative expenses surged by 166% in Q3 2025 to $39.467 million and 59% for the nine months to $69.454 million, largely due to a $23.1 million litigation provision.
• Net cash provided by operating activities decreased by $61.11 million for the nine months ended September 30, 2025, compared to the prior year.
• A jury verdict on October 22, 2025, awarded a plaintiff $34.1 million in a personal injury lawsuit, with $23.1 million not covered by insurance and accrued in Q3 2025.

Risks

• Adverse impacts of global conflicts, challenging macroeconomic conditions, and market uncertainty on business, financial condition, operations, cash flows, and liquidity.
• Risks associated with single-source suppliers and the ability to secure sufficient quantities of raw materials, APIs, and components, especially from foreign sources.
• Interruptions to manufacturing and production due to natural catastrophic events, power disruptions, pandemics, wars, terrorist attacks, or other causes beyond control.
• Uncertainty regarding the timing and likelihood of FDA approvals and regulatory actions on product candidates, manufacturing activities, and product marketing.
• Ability to compete in the development and marketing of products and product candidates, potentially leading to price concessions or exclusion of suppliers.
• Effects of reforms in healthcare regulations and reductions in pharmaceutical pricing, reimbursement, and coverage, including potential drug price controls.
• Variations in intellectual property laws, ability to establish and maintain IP protection, and ability to defend IP in cases of alleged infringement.
• Potential for exposure to product liability claims.
• Challenges in successfully bidding for suitable acquisition targets or licensing opportunities, or in consummating and integrating acquisitions, divestitures, or investments.
• Risks associated with expanding internationally, including political unrest, tariffs, and changes in foreign government policies.
• Potential for business and operations to be impacted by system breaches or failures, including cyber-attacks, data loss, and disruptions to supply chain processes.
• Risks associated with executive officers pledging shares as collateral for loans, which could lead to forced sales and stock price decline.
• Results of litigation and claims are inherently unpredictable and can have an adverse impact due to defense and settlement costs, diversion of management resources, and other factors.
• Future cash requirements include significant milestone payments for the BAQSIMI acquisition (up to $575 million) and potential development/sales milestones for new licensing agreements (e.g., Anji agreement up to $267 million).
• Anticipated continued decline in glucagon sales due to competitive dynamics.
• Anticipated fluctuation in epinephrine and other product sales depending on competitors' ability to supply market demands.
• Expectation that R&D expenses will increase significantly over the next several quarters and years due to increased clinical trials costs for insulin and inhalation product candidates.

Future Outlook

Glucagon sales are anticipated to continue declining due to competitive dynamics. Sales of epinephrine and other products are expected to fluctuate based on competitors' supply capabilities. Selling, distribution, and marketing expenses are projected to increase due to expanded marketing for BAQSIMI and Primatene MIST. Research and development expenses are expected to rise annually and significantly over the next several quarters and years, driven by increased clinical trial costs for insulin and inhalation product candidates. Cash requirements are expected to increase significantly in the foreseeable future due to potential milestone payments for the BAQSIMI acquisition (up to $575 million), clinical trials, regulatory approvals, product development, manufacturing, marketing, and strategic acquisitions. Facility expansion projects in the U.S. and China are planned, to be funded by operating cash flows. The company believes its current cash reserves, operating cash flows, and credit facilities will be sufficient for operations for at least the next 12 months. The One Big Beautiful Bill Act is not expected to materially impact income tax expense but may alter the timing of cash tax payments.

Management Comments

• "We anticipate that sales of glucagon will continue to decline in the future due to competitive dynamics."
• "We also anticipate that sales of epinephrine and other products will continue to fluctuate depending on the ability of our competitors to supply market demands."
• "We expect that selling, distribution and marketing expenses will continue to increase due to the increase in marketing expenditures for BAQSIMI and Primatene MIST."
• "Legal fees may fluctuate from period to period due to the timing of patent challenges and other litigation matters."
• "We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business."
• "We expect that research and development expenses will increase on an annual basis due to increased clinical trials costs related to our insulin and inhalation product candidates."
• "As we undertake new and challenging research and development projects, we anticipate that the associated costs will increase significantly over the next several quarters and years."
• "We believe that our cash reserves, operating cash flows, and borrowing availability under our credit facilities will be sufficient to fund our operations for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q."

Industry Context

The pharmaceutical industry is highly competitive, as evidenced by declining sales of Glucagon, Epinephrine, and Lidocaine due to increased competition and shifts to newer, ready-to-use products like BAQSIMI. The company's focus on technically challenging generic and proprietary injectable, inhalation, and intranasal products, along with insulin API, positions it in specialized segments. The acquisition of BAQSIMI and subsequent global distribution assumption reflects a strategy to leverage proprietary products in a competitive landscape. Increased R&D investment in insulin and inhalation product candidates aligns with industry trends towards innovation and pipeline expansion. The impact of healthcare reforms and potential drug price controls is a pervasive industry trend affecting all pharmaceutical companies.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• A former employee initiated an employment litigation on April 15, 2024, against Amphastar and IMS for alleged violations of the California Labor Code (PAGA, wage and hour, etc.). Individual and class claims were dismissed in November 2024, with only the PAGA claim remaining. The company intends to vigorously defend itself.
• A former employee initiated an employment litigation on June 20, 2024, against Amphastar, IMS, and Roth Staffing Companies L.P. for alleged violations of the California Labor Code (wage and hour, etc.). The company intends to vigorously defend itself.
• A personal injury lawsuit, initiated on August 23, 2023, resulted in a jury verdict on October 22, 2025, awarding the plaintiff $34.1 million. $11.0 million is covered by the company's insurance policies, and $23.1 million was accrued in Q3 2025 as general and administrative expense. The company is exploring all post-verdict options, including an appeal.
• The company is subject to various other claims, arbitrations, investigations, and lawsuits from time to time arising in the ordinary course of business.

Related Party Transactions

• The company has an 11.5% ownership in Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (Hanxin), which is considered a related party due to management and ownership interests of Dr. Jack Zhang, Dr. Mary Luo, and Henry Zhang (Dr. Zhang's son).
• Under contract manufacturing agreements with Hanxin, the company recognized an immaterial amount of revenue in Q3 2025 and $0.3 million for the nine months ended September 30, 2025. Receivables from Hanxin were approximately $0.5 million as of September 30, 2025.
• A Contract Research Agreement was entered into with Hanxin on September 15, 2025, for the development of Recombinant Human Insulin Research Cell Banks and Recombinant Peptide Research Cell Banks (RCBs) and scale-up manufacturing process development. Immaterial payments were made in Q3 2025.
• Nanjing Letop Biotechnology Co., Ltd. (Letop) is a related party due to Henry Zhang's ownership. Under a supply agreement from November 2022, Letop manufactures chemical intermediates for the company on a cost-plus basis, with immaterial payments made in Q3 2025.
• Hong Kong Genreach Limited (Genreach), a wholly-owned subsidiary of Hanxin, entered into a distribution agreement in August 2024 to be the exclusive distributor for Primatene MIST in Greater China. No revenue was recognized from this agreement in Q3 2025.
• Nanjing Chengong Pharmaceutical Co., Limited (Chengong), a wholly-owned subsidiary of Hanxin, entered into a distribution agreement on October 21, 2025, to be the exclusive distributor for BAQSIMI in Greater China. Chengong is responsible for regulatory approvals and post-marketing clinical trials for BAQSIMI in the region.

Stakeholder Impact

• Shareholders: Negative impact from reduced net income and EPS, and the significant litigation expense. Positive impact from increased share buyback authorization. Potential long-term benefits from new licensing agreements and R&D investments. Risk of stock price decline due to executive share pledges.
• Employees: Share-based compensation is a component of overall compensation. No direct impact on employment levels or benefits was explicitly mentioned.
• Customers: Continued supply of key products like BAQSIMI and Primatene MIST. New product launches (Iron Sucrose Injection) expand offerings. Potential for new products from Anji licensing.
• Suppliers: Continued reliance on single-source and foreign suppliers, posing supply chain risks.
• Creditors: The company remains in compliance with all debt covenants. Cash position remains strong, supporting debt obligations.

Next Steps

• Continue sales and marketing efforts for BAQSIMI and Primatene MIST.
• Make substantial investments in research and development to expand the product portfolio, particularly for insulin and inhalation product candidates.
• Undertake new and challenging R&D projects.
• Upgrade, expand, and improve manufacturing facilities in the United States and China.
• Explore post-verdict options, including an appeal, for the personal injury lawsuit.
• Develop, make, use, and commercialize three identified products in the US and Canada under the Anji License Agreement.
• Nanjing Chengong Pharmaceutical Co., Limited to obtain regulatory approvals and perform post-marketing clinical trials for BAQSIMI in Greater China.
• Nanjing Hanxin Pharmaceutical Technology Co., Ltd. to research and develop Recombinant Human Insulin Research Cell Banks and Recombinant Peptide Research Cell Banks for the Company.

Key Dates

Recommendation

The company presents a mixed bag of results. Strong growth in BAQSIMI and Primatene MIST, coupled with new product launches and strategic licensing agreements, indicates a healthy underlying business and future growth potential. The increased share buyback authorization is a positive signal for shareholder value. However, the significant decline in overall net income and EPS, primarily due to a large, uninsured litigation expense, and the continued decline in sales of other established products (Glucagon, Epinephrine, Lidocaine) due to competition, introduce considerable uncertainty and risk. The increased R&D spending is necessary for future growth but will weigh on short-term profitability. Investors should hold, monitoring the outcome of the appeal for the personal injury lawsuit, the integration and development of new licensed products, and the company's ability to stabilize sales of its declining products while growing its newer portfolio. The long-term strategy appears sound, but short-to-medium term execution and risk management are critical.

Keywords

Pharmaceuticals, Biopharmaceutical, 10-Q, Amphastar, BAQSIMI, Primatene MIST, Glucagon, Epinephrine, Lidocaine, Iron Sucrose Injection, Drug Development, Generic Drugs, Injectable Products, Inhalation Products, Intranasal Products, API, Financial Results, Q3 2025, Earnings, Revenue, Net Income, Operating Expenses, Litigation, Share Buyback, Licensing Agreement, China Operations, Supply Chain, Regulatory Approval, FDA, Clinical Trials, Corporate Governance, Risk Factors